McKesson (MCK) Investor Day 2025 summary

Strategic priorities and business evolution

• Four growth pillars: people/culture, oncology/multispecialty/biopharma services, North American pharmaceutical distribution, and portfolio modernization.

• Recent portfolio changes include the separation of the medical surgical business into an independent company and a new segment structure focused on North American pharmaceutical, oncology/multispecialty, and prescription technology solutions.

• Investments in automation, AI, digital transformation, and technology modernization are central to operational efficiency and customer experience.

• Strategic acquisitions have expanded capabilities in clinical trials, prescription technology, and specialty care, including expansion into retina and ophthalmology.

• Emphasis on people, culture, and leadership development as foundational to sustained growth.

Financial performance and guidance

• Fiscal 2026 guidance raised: adjusted operating profit growth of 10%-14% and adjusted EPS growth of 15%-17% (17%-19% excluding venture gains), with FY26 adjusted EPS guidance at $38.05–$38.55.

• Oncology and multispecialty segment expected to deliver 27%-31% revenue growth and 49%-53% adjusted operating profit growth, driven by organic volumes and recent acquisitions.

• Prescription Technology Solutions segment guidance increased to 9%-13% revenue growth and 11%-15% adjusted operating profit growth, reflecting strong demand for access and affordability solutions.

• Long-term adjusted EPS growth target updated to 13%-16%, with oncology/multispecialty AOP growth targeted at 13%-16% and North American pharmaceutical at 5%-8%.

• Free cash flow expected at $4.4–$4.8 billion in FY26, with a robust balance sheet and leverage targeted at ~1.3x.

Business segment highlights and market trends

• North American pharmaceutical services integrates U.S. and Canadian distribution, leveraging best practices and scale, with 1/3 of pharmaceuticals distributed in the region and >99% inventory service level.

• Specialty pharmaceuticals, especially oncology and immunology, are key growth drivers, now representing over half of U.S. pharmaceutical market spend.

• Canadian operations focus on technology, automation, and expanding specialty drug access, with the largest independent pharmacy network and expanded specialty health solutions.

• Oncology and multispecialty platform supports 3,300+ providers and 2.4 million annual patient visits, with a strong focus on community-based care and clinical research.

• Prescription Technology Solutions business supports over 700 programs for nearly 200 biopharma partners, with GLP-1 therapies representing 11% of segment revenue.